Linnea SA

Linnea SA is a Swiss company specializing in the production of botanical active pharmaceutical ingredients and standardized botanical ingredients for the dietary supplement and pharmaceutical sectors. Founded in 1982 in Switzerland, Linnea SA focuses on manufacturing high-quality botanical active pharmaceutical ingredients. The company has maintained its core operations while being fully acquired in March 2025 by Vivalto Partners and its management from Ipsen Group and Dr. Willmar Schwabe GmbH & Co.

KG. The founder's history is not detailed in the available information. Linnea specializes in the manufacturing of high-quality botanical active pharmaceutical ingredients (APIs) and standardized botanical ingredients tailored for the dietary supplement and pharmaceutical industries. The company’s core product offerings include Linnea® Butylscopolamine, Linnea® Red Clover, Linnea® Cannabinoids, and Linnea® HMRlignan®, among others.

These products are designed to address various health and wellness needs, including therapeutic uses that are substantiated by targeted clinical studies. Linnea’s ingredients serve a diverse clientele, including pharmaceutical companies and dietary supplement manufacturers, across multiple geographical markets such as Europe, Asia, and North America. This extensive reach demonstrates Linnea's commitment to providing innovative and sustainable solutions to enhance health globally. Linnea operates primarily through B2B transactions, supplying its botanical ingredients to pharmaceutical firms and dietary supplement manufacturers.

The revenue structure is based on direct sales agreements where clients place bulk orders for Linnea’s proprietary products, such as Linnea® Vinpocetine and Linnea® Ginkgo Biloba. These transactions typically involve long-term partnerships with clients, allowing for tailored supply agreements that accommodate the specific needs of manufacturers in different regions. While specific pricing plans for individual products have not been outlined, the transaction framework suggests a focus on competitive pricing strategies that provide value to Linnea’s clients. The company's established reputation in the market supports ongoing sales and fosters new business opportunities within the industry.

As part of its growth strategy, Linnea SA is set to enhance its manufacturing capabilities following its acquisition in March 2025. The company aims to develop new botanical ingredients, with specific details regarding upcoming products to be announced. There are also plans to expand into new geographic markets, although specific regions have not been identified. The recent acquisition by Vivalto Partners will support these initiatives, enhancing Linnea's manufacturing capabilities in the pharmaceutical sectors.